• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Microbiol Infect . Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-Cov-2 inf

tetano

Editor, Senior Moderator
Clin Microbiol Infect


. 2020 Aug 8;S1198-743X(20)30479-1.
doi: 10.1016/j.cmi.2020.08.003. Online ahead of print.
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-Cov-2 infection: a multicenter cohort study (PREDI-CO study)


Michele Bartoletti[SUP] 1 [/SUP], Maddalena Giannella[SUP] 2 [/SUP], Luigia Scudeller[SUP] 3 [/SUP], Sara Tedeschi[SUP] 4 [/SUP], Matteo Rinaldi[SUP] 4 [/SUP], Linda Bussini[SUP] 4 [/SUP], Giacomo Fornaro[SUP] 4 [/SUP], Renato Pascale[SUP] 4 [/SUP], Livia Pancaldi[SUP] 4 [/SUP], Zeno Pasquini[SUP] 5 [/SUP], Filippo Trapani[SUP] 4 [/SUP], Lorenzo Badia[SUP] 4 [/SUP], Caterina Campoli[SUP] 4 [/SUP], Marina Tadolini[SUP] 4 [/SUP], Luciano Attard[SUP] 4 [/SUP], Massimo Puoti[SUP] 6 [/SUP], Marco Merli[SUP] 6 [/SUP], Cristina Mussini[SUP] 7 [/SUP], Marianna Menozzi[SUP] 7 [/SUP], Marianna Meschiari[SUP] 7 [/SUP], Mauro Codeluppi[SUP] 8 [/SUP], Francesco Barchiesi[SUP] 5 [/SUP], Francesco Cristini[SUP] 9 [/SUP], Annalisa Saracino[SUP] 10 [/SUP], Alberto Licci[SUP] 11 [/SUP], Silvia Rapuano[SUP] 12 [/SUP], Tommaso Tonetti[SUP] 13 [/SUP], Paolo Gaibani[SUP] 14 [/SUP], Vito Marco Ranieri[SUP] 13 [/SUP], Pierluigi Viale[SUP] 4 [/SUP], PREDICO study group



Collaborators, Affiliations

Abstract

Objectives: We aimed to develop and validate a risk score to predict severe respiratory failure (SRF) among patients hospitalized with coronavirus disease-2019 (COVID-19).
Methods: We performed a multicentre cohort study among hospitalized (>24 hours) patients diagnosed with COVID-19 from February 22 to April 3 2020, at 11 Italian hospitals. Patients were divided into derivation and validation cohorts according to random sorting of hospitals. SRF was assessed from admission to hospital discharge and was defined as: SpO2<93% with 100% FiO2, respiratory rate (RR)>30bpm, or respiratory distress. Multivariable logistic regression models were built to identify predictors of SRF, β-coefficients were used to develop a risk score. Trial Registration NCT04316949.
Results: We analyzed 1113 patients (644 derivation, 469 validation cohort). Mean (?standard deviation)age was 65.7(?15) years, 704 (63.3%) were male. SRF occurred in 189/644 (29%) and 187/469 (40%) patients in derivation and validation cohort, respectively. At multivariate analysis, risk factors for SRF in the derivation cohort assessed at hospitalization were age ≥70 years [OR 2.74 (95%CI 1.66-4.50)], obesity [OR 4.62 (95%CI 2.78-7.70)], body temperature ≥38?C [OR 1.73 (95%CI 1.30-2.29)], RR ≥22bpm [OR 3.75 (95%CI 2.01-7.01)], lymphocytes ≤900/mm[SUP]3[/SUP] [OR 2.69 (95%CI 1.60-4.51)], creatinine ≥1 mg/dl [OR 2.38 (95%CI 1.59-3.56)], C-reactive protein ≥10mg/dl [OR 5.91 (95%CI 4.88-7.17)], and lactate dehydrogenase ≥350IU/L[OR 2.39 (95%CI 1.11-5.11)]. Assigning points to each variable an individual risk score (PREDI-CO score) was obtained. Area under receiver-operator curve (AUROC) was 0.89 (0.86-0.92). At score of >3, sensitivity, specificity, positive and negative predictive values were 71.6%(65-79%), 89.1% (86-92%), 74%(67-80%), and 89%(85-91%), respectively;. PREDI-CO score showed similar prognostic ability in the validation cohort: AUROC 0.85 (0.81-0.88). At score of >3, sensitivity, specificity, positive and negative predictive values were 80% (73-85%), 76 (70-81%), 69%(60-74%) and 85% (80-89%), respectively.
Conclusion: PREDI-CO score can be useful to allocate resources and prioritize treatments during COVID-19 pandemic.

Keywords: COVID-19; SARS-CoV-2; prognostic tool; severe respiratory failure.
 
Back
Top Bottom